From Tissues to Fever Reducers: $50 Billion Healthcare Mega Deal Shareholder Approval

U.S. consumer goods company Kimberly-Clark Corporation (KMB) and consumer health firm Kenvue Inc. (KVUE) secured overwhelming approval at a special shareholder meeting to authorize new share issuance and ratify the merger agreement. About 96% of Kimberly-Clark shareholders and roughly 99% of Kenvue shareholders voted in favor, clearing a critical deal milestone. Pending regulatory clearance and customary closing steps, the transaction is slated to close in the second half of 2026, with both companies aiming to combine their consumer brands into a global leader in healthcare and wellness. (kenvue.com)

Earlier, in its late-January quarterly results, Kimberly-Clark reported improved profitability and reiterated its strategy to broaden its long-term growth foundation by acquiring Kenvue for over $40 billion (approximately KRW 50–60 trillion). During the deal process, both companies’ share prices showed volatility, yet Kenvue’s stock rose slightly on January 30 despite a weak market, indicating investor interest in the progress of this major transaction. (wsj.com)

Kimberly-Clark is a global essential-consumer-products company operating in more than 175 countries with hygiene and household brands such as Kleenex and Huggies. Kenvue, spun off from Johnson & Johnson, specializes in consumer health and owns brands including Tylenol, Neutrogena and Listerine. Once the acquisition is complete, it is expected to reshape the competitive landscape of the global healthcare and wellness consumer-goods market, particularly in North America. (investors.kenvue.com)